Mission

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by debilitating motor and non-motor symptoms. Historically diagnosed only after significant motor impairment has occurred, patients often face irreversible quality-of-life deterioration. NeuroFore is committed to changing this narrative by identifying Parkinson’s disease during the earliest, crucial stages when effective interventions can significantly alter patient trajectories.

Over 10 million people globally currently live with Parkinson's disease, marking it as the second most prevalent neurodegenerative disorder worldwide. Parkinson’s disease cases are projected to surge to 17 million by 2040.

Non-motor symptoms, including sleep disorders, loss of smell, cognitive decline, and mood disorders, precede motor symptoms by several years, yet remain vastly underutilized in early diagnostic practices.

Current diagnostic methods relying solely on motor symptoms lead to delayed diagnosis, resulting in severe, irreversible health consequences and significantly increased healthcare costs.